ClinicalTrials.Veeva

Menu

Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults

Zhejiang University logo

Zhejiang University

Status

Unknown

Conditions

Obesity
Non-Alcoholic Fatty Liver Disease

Treatments

Behavioral: Lifestyle education
Behavioral: Intensive lifestyle intervention
Behavioral: Hypocaloric low-carbohydrate diet plan

Study type

Interventional

Funder types

Other

Identifiers

NCT03972631
CHPF2018-NALFD-1

Details and patient eligibility

About

Lifestyle intervention is the most important management of non-alcoholic fatty liver diseases (NAFLD) patients. Weight reductions of 5-10% can improve non-alcoholic steatosis and fibrosis. However, the options for treatment in the clinics are limited. Therefore, in this study, we investigated the effectiveness of different lifestyle intervention strategies in NAFLD patients.

Full description

This is a multicenter, randomized clinical trial nested within a cohort study in overweight and obese non-alcoholic fatty liver diseases (NAFLD) patients. In this study, 1500 eligible patients will be recruited, and demographic information and clinical data will be collected at baseline. Among these, 292 participants who agree to be randomized will be randomized into two intervention groups, including lifestyle education (LE), and intensive lifestyle intervention with low-carbohydrate diet (ILI), aiming to induce a loss ≥ 10% of initial weight in 3 months. The remainder will chose the treatment which they prefer according to the clinical practice. At the 3th, 6th and 12th month, all the participants will be followed, and data will be collected to study the development of NAFLD in different lifestyle intervention groups.

Enrollment

292 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Man or women aged 18-65 years;
  • Confirmed diagnosis of NAFLD according to the 2018 Chinese Guidelines for Prevention and Treatment of NAFLD;
  • Body mass index (BMI)of 25.0 to 35.0 kg/m2;
  • Patients without medicine for treatment of NAFLD;

Exclusion criteria

  • Patients with other diseases that can lead to fatty liver;
  • Patients use amiodaron, methotrexate, tamoxifen, glucocorticoid, estrogen, and the other medications that affect weight within 3 months;
  • Patients with serious liver dysfunction (AST or/and ALT >3 times of the upper limit of normal), or renal dysfunction (serum creatinine >the upper limit of normal);
  • Patients with diseases that need control of dietary protein intake;
  • Patients with diseases that affect food digestion and absorption;
  • Patients with diagnosed diabetes or those with significantly elevated blood glucose (fasting blood glucose ≥7.0 mmol/L and/or random blood glucose ≥11.1 mmol/L);
  • Patients with severe cardiovascular and cerebrovascular diseases or severe hypertension (Grade 3); anemia; mental illness or memory disorder; epilepsy or antiepileptic treatment;
  • Patients with secondary obesity;
  • Patients with cancer, active tuberculosis, AIDS and other infectious diseases;
  • Pregnancy or lactation;
  • Physical disability.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

292 participants in 2 patient groups, including a placebo group

Lifestyle education
Placebo Comparator group
Description:
The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
Treatment:
Behavioral: Lifestyle education
Intensive Lifestyle Intervention
Experimental group
Description:
The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
Treatment:
Behavioral: Hypocaloric low-carbohydrate diet plan
Behavioral: Intensive lifestyle intervention
Behavioral: Lifestyle education

Trial contacts and locations

0

Loading...

Central trial contact

Zhong Liu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems